THURSDAY, June 2, 2022 (HealthDay News) — In an additional issue of Diabetic treatmentsthe American Diabetes Association has released updates to the new Standards of medical care for diabetes – 2022.
The updates include changes to Section 10, which deals with cardiovascular disease and risk management, and Section 11, which deals with chronic kidney disease and risk management. Recent updates offer information regarding the effects of finerenone on cardiovascular outcomes in people with type 2 diabetes and chronic kidney disease and the effects of sodium-glucose cotransporter 2 inhibitors on heart failure and chronic kidney disease. kidney outcomes in people with type 2 diabetes. New information was also included on the calculation of estimated glomerular filtration rates and the inclusion of race in the diagnosis of kidney disease.
“This is the fifth year that we have been able to update the Standards of care after its publication on our Care living standards updates, helping to provide diabetes care providers with the most important information and latest scientific evidence relevant to their practice,” said Robert Gabbay, MD, Scientific and Medical Director of the American Diabetes Association, in a statement. .
Several authors disclosed financial ties to the pharmaceutical industry.
Addendum. 10. Cardiovascular diseases and risk management
Addendum. 11. Chronic Kidney Disease and Risk Management
Standards of medical care for diabetes – 2022